CoChat

First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies.

Open access

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Animal embryotoxicity data, and the scarcity of safety data in human pregnancies, have prevented artemisinin derivatives from being recommended for malaria treatment in the first trimester except in lifesaving circumstances. We conducted a meta-analysis of prospective observational studies comparing the risk of miscarriage, stillbirth, and major congenital anomaly (primary outcomes) among first-trimester pregnancies treated with artemisinin derivatives versus quinine or no antimalarial treatment. METHODS AND FINDINGS: Electronic databases including Medline, Embase, and Malaria in Pregnancy Library were searched, and investigators contacted. Five studies involving 30,618 pregnancies were included; four from sub-Saharan Africa (n = 6,666 pregnancies, six sites) and one from Thailand (n = 23,952). Antimalarial exposures were ascertained by self-report or active detection and confirmed by prescriptions, clinic cards, and outpatient registers. Cox proportional hazards models, accounting for time under observation and gestational age at enrollment, were used to calculate hazard ratios. Individual participant data (IPD) meta-analysis was used to combine the African studies, and the results were then combined with those from Thailand using aggregated data meta-analysis with a random effects model. There was no difference in the risk of miscarriage associated with the use of artemisinins anytime during the first trimester (n = 37/671) compared with quinine (n = 96/945; adjusted hazard ratio [aHR] = 0.73 [95% CI 0.44, 1.21], I2 = 0%, p = 0.228), in the risk of stillbirth (artemisinins, n = 10/654; quinine, n = 11/615; aHR = 0.29 [95% CI 0.08-1.02], p = 0.053), or in the risk of miscarriage and stillbirth combined (pregnancy loss) (aHR = 0.58 [95% CI 0.36-1.02], p = 0.099). The corresponding risks of miscarriage, stillbirth, and pregnancy loss in a sensitivity analysis restricted to artemisinin exposures during the embryo sensitive period (6-12 wk gestation) were as follows: aHR = 1.04 (95% CI 0.54-2.01), I2 = 0%, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0.551; and aHR = 0.98 (95% CI 0.52-2.04), p = 0.603. The prevalence of major congenital anomalies was similar for first-trimester artemisinin (1.5% [95% CI 0.6%-3.5%]) and quinine exposures (1.2% [95% CI 0.6%-2.4%]). Key limitations of the study include the inability to control for confounding by indication in the African studies, the paucity of data on potential confounders, the limited statistical power to detect differences in congenital anomalies, and the lack of assessment of cardiovascular defects in newborns. CONCLUSIONS: Compared to quinine, artemisinin treatment in the first trimester was not associated with an increased risk of miscarriage or stillbirth. While the data are limited, they indicate no difference in the prevalence of major congenital anomalies between treatment groups. The benefits of 3-d artemisinin combination therapy regimens to treat malaria in early pregnancy are likely to outweigh the adverse outcomes of partially treated malaria, which can occur with oral quinine because of the known poor adherence to 7-d regimens. REVIEW REGISTRATION: PROSPERO CRD42015032371.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002290

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flow diagram of studies and participants included in meta-analysis for miscarriage, stillbirth, and congenital anomaly. ACT, artemisinin combination therapy; ANC, antenatal care; IPD, individual participant data.
Fig 1 Flow diagram of studies and participants included in meta-analysis for miscarriage, stillbirth, and congenital anomaly. ACT, artemisinin combination therapy; ANC, antenatal care; IPD, individual participant data.CC0 · PubMed Central
Fig 2 Forest plot for aggregated data meta-analysis of crude and adjusted hazard ratios for the association between different antimalarial exposure categories and miscarriage. HRs account for pregnancy week under observation through left truncation and treat exposure as a time-dependent variable. I2 values are for IPD from Africa only: a26.4%; b26.0%; c23.9%; d30.5%; e26.1%; f28.9%. Crude HRs are adjusted for clustering by site in the IPD arm. aHRs for IPD from Africa account for site, woman’s age, and gravidity. aHRs for the SMRU account for smoking, year of first consultation, gravidity, and non-malaria febrile morbidity in first trimester for the comparison with the unexposed group, while the comparison between the artemisinin and quinine groups accounts for infection severity (asymptomatic, symptomatic, hyperparasitemic/severe), year of first consultation, and non-malaria febrile morbidity in the first trimester. aHR, adjusted hazard ratio; HR, hazard ratio; IPD, individual patient data; SMRU, Shoklo Malaria Research Unit.
Fig 2 Forest plot for aggregated data meta-analysis of crude and adjusted hazard ratios for the association between different antimalarial exposure categories and miscarriage. HRs account for pregnancy week under observation through left truncation and treat exposure as a time-dependent variable. I2 values are for IPD from Africa only: a26.4%; b26.0%; c23.9%; d30.5%; e26.1%; f28.9%. Crude HRs are adjusted for clustering by site in the IPD arm. aHRs for IPD from Africa account for site, woman’s age, and gravidity. aHRs for the SMRU account for smoking, year of first consultation, gravidity, and non-malaria febrile morbidity in first trimester for the comparison with the unexposed group, while the comparison between the artemisinin and quinine groups accounts for infection severity (asymptomatic, symptomatic, hyperparasitemic/severe), year of first consultation, and non-malaria febrile morbidity in the first trimester. aHR, adjusted hazard ratio; HR, hazard ratio; IPD, individual patient data; SMRU, Shoklo Malaria Research Unit.CC0 · PubMed Central
Fig 3 Forest plot for aggregated data meta-analysis of crude and adjusted hazard ratios for the association between different antimalarial exposure categories and stillbirth. HRs account for pregnancy week under observation through left truncation and treat exposure as a time-dependent variable. I2 values are for IPD from Africa only: a26.0%; b27.4%; c26.1%; d28.3%; e20.5%; f27.0%. Crude HRs are adjusted for clustering by site. aHRs for IPD from Africa account for site, woman’s age, and gravidity. aHRs for the SMRU account for smoking, year of first consultation, gravidity, and non-malaria febrile morbidity in the first trimester for the comparison with the unexposed group. aHR, adjusted hazard ratio; HR, hazard ratio; IPD, individual patient data; SMRU, Shoklo Malaria Research Unit.
Fig 3 Forest plot for aggregated data meta-analysis of crude and adjusted hazard ratios for the association between different antimalarial exposure categories and stillbirth. HRs account for pregnancy week under observation through left truncation and treat exposure as a time-dependent variable. I2 values are for IPD from Africa only: a26.0%; b27.4%; c26.1%; d28.3%; e20.5%; f27.0%. Crude HRs are adjusted for clustering by site. aHRs for IPD from Africa account for site, woman’s age, and gravidity. aHRs for the SMRU account for smoking, year of first consultation, gravidity, and non-malaria febrile morbidity in the first trimester for the comparison with the unexposed group. aHR, adjusted hazard ratio; HR, hazard ratio; IPD, individual patient data; SMRU, Shoklo Malaria Research Unit.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. R Clark, 2006, Artesunate: developmental toxicity in monkeys, Birth Defects Res A Clin Mol Teratol, 76, 329

Cited by

See all 90

Metadata

Authors
Dellicour, S., Sevene, E., McGready, R., Tinto, H., Mosha, D., Manyando, C., Rulisa, S., Desai, M., Ouma, P., Oneko, M., Vala, A., Rupérez, M., Macete, E., Menéndez, C., Nakanabo-Diallo, S., Kazienga, A., Valéa, I., Calip, G., Augusto, O., Genton, B., Njunju, E. M., Moore, K. A., d’Alessandro, U., Nosten, F., ter Kuile, F., & Stergachis, A.
Affiliations
  • University of Liverpool (GB)
  • Eduardo Mondlane University (MZ)
  • Mahidol University (TH)
  • Centre Muraz (BF)
  • Ifakara Health Institute (TZ)
  • Tropical Diseases Research Centre (ZM)
  • University of Rwanda (RW)
  • Centers for Disease Control and Prevention (US)
  • Kenya Medical Research Institute (KE)
  • Manhiça Health Research Centre (MZ)
  • University of Illinois Chicago (US)
  • Swiss Tropical and Public Health Institute (CH)
  • Copperbelt University (ZM)
  • Burnet Institute (AU)
  • London School of Hygiene & Tropical Medicine (GB)
  • University of Washington (US)
Corresponding author
  • Dellicour, Stephanie
  • Stergachis, Andy
Venue
PLOS Medicine
Published
2017-05-02
Volume
14
Issue
5
Pages
e1002290
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2610284326
Cited by
90
References
49
Citations by year
2026: 4 · 2025: 4 · 2024: 1 · 2023: 12 · 2022: 13 · 2021: 4 · 2020: 29 · 2019: 9 · 2018: 9 · 2017: 5
FWCI
2.29
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion, other-oa)
  • SERVAL (Université de Lausanne) (publishedVersion, other-oa)
  • LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
  • IHI Repository (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • IRIS (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • edoc (University of Basel) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Bill and Melinda Gates Foundation (Malaria in Pregnancy Consortium)
  • Wellcome Trust (Shoklo Malaria Research Unit)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
artemisinin derivatives, quinine, malaria in pregnancy, first trimester, miscarriage, stillbirth, major congenital malformations, antimalarial drug safety, sub-Saharan Africa, Thailand, drug safety in pregnancy
MeSH terms
Abnormalities, Drug-Induced, Abortion, Spontaneous, Asia, Southeastern, Female, Humans, Pregnancy, Pregnancy Trimester, First, Quinine, Prevalence, Africa South of the Sahara, Risk Assessment, Artemisinins, Stillbirth, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. https://app.cochat.ai/papers/10.1371/journal.pmed.1002290
The paper
Dellicour, S., Sevene, E., McGready, R., Tinto, H., Mosha, D., Manyando, C., Rulisa, S., Desai, M., Ouma, P., Oneko, M., Vala, A., Rupérez, M., Macete, E., Menéndez, C., Nakanabo-Diallo, S., Kazienga, A., Valéa, I., Calip, G., Augusto, O., . . . Stergachis, A. (2017). First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.